Cheplapharm and Sanofi Move to Forge Strategic Partnership – Lovenox/Clexane Anchors 20‑Medicine Portfolio and Three‑Site Transfer in Exchange for 26.4 % Equity Stake
CompanyDeals

Cheplapharm and Sanofi Move to Forge Strategic Partnership – Lovenox/Clexane Anchors 20‑Medicine Portfolio and Three‑Site Transfer in Exchange for 26.4 % Equity Stake

Cheplapharm and Sanofi (NASDAQ: SNY) announced their intention to form a strategic partnership, under which Cheplapharm will take over a selection of 20 mature medicines worldwide — including the anticoagulant…

Hengrui's SHR‑2004 Marketing Application Accepted by NMPA – First‑in‑Class FXI Antibody Nears Approval for VTE Prevention in Knee Replacement
CompanyDrug

Hengrui’s SHR‑2004 Marketing Application Accepted by NMPA – First‑in‑Class FXI Antibody Nears Approval for VTE Prevention in Knee Replacement

China Medical System Wins NMPA Clinical Trial Approval for CMS‑D001 – Highly Selective Oral TYK2 Inhibitor Targeting Systemic Lupus Erythematosus
CompanyDrug

China Medical System Wins NMPA Clinical Trial Approval for CMS‑D001 – Highly Selective Oral TYK2 Inhibitor Targeting Systemic Lupus Erythematosus

Ascentage Pharma Forges Strategic Research Collaboration with Peking University – Building a Collaborative Innovation System in Hematologic Oncology
CompanyDeals

Ascentage Pharma Forges Strategic Research Collaboration with Peking University – Building a Collaborative Innovation System in Hematologic Oncology

Eisai and Sinopharm Forge Promotional Partnership for Methycobal Injection – Full‑Lifecycle Collaboration to Broaden Access to Vitamin B12 Therapy in China
CompanyDeals

Eisai and Sinopharm Forge Promotional Partnership for Methycobal Injection – Full‑Lifecycle Collaboration to Broaden Access to Vitamin B12 Therapy in China

- Advertisement -
Ad image
CompanyDrug

TJ Biopharma and Biogen Win NMPA Approval for Felzartamab (JINGFEI) in Multiple Myeloma – First Commercial Milestone Under Greater China Licensing Deal

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies
CompanyDeals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

CompanyDeals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

CompanyDeals

Insilico Medicine and THPharma Launch AI Research Collaboration to Build ‘Reverse Translation’ Drug Discovery Strategy Around Phase 3 Candidate THP-001

CompanyDrug

Ark Biopharmaceutical’s First-in-Class AFC AK0406 Wins NMPA Approval for Influenza Prevention Clinical Trials

CompanyDrug

Youcare Pharmaceutical’s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis

AstraZeneca and Daiichi Sankyo's Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab
CompanyDrug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

CompanyDrug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

CompanyDeals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

CompanyDrug

IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform

CompanyDrug

Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy

CompanyDeals

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Show More